Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
47
AMED Quote, Financials, Valuation and Earnings
Last price:
$84.56
Seasonality move
:
8.5%
Day range:
$82.15 - $84.87
52-week range:
$82.15 - $98.95
Dividend yield:
0%
P/E ratio:
33.53x
P/S ratio:
1.20x
P/B ratio:
2.41x
Volume:
2.3M
Avg. volume:
720.6K
1-year change:
-11.09%
Market cap:
$2.8B
Revenue:
$2.2B
EPS (TTM):
$2.52
Analysts' Opinion
-
Consensus RatingAmedisys has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Amedisys has an estimated upside of 14.02% from its current price of $84.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $84.49.
Fair Value
-
According to the consensus of 0 analysts, Amedisys has 14.02% upside to fair value with a price target of -- per share.
AMED vs. S&P 500
-
Over the past 5 trading days, Amedisys has overperformed the S&P 500 by 0.61% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Amedisys does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amedisys has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Amedisys reported revenues of $587.7M.
Earnings Growth
-
Amedisys earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Amedisys reported earnings per share of $0.51.
Enterprise value:
3B
EV / Invested capital:
1.87x
Price / LTM sales:
1.20x
EV / EBIT:
17.74x
EV / Revenue:
1.27x
PEG ratio (5yr expected):
0.01x
EV / Free cash flow:
14.52x
Price / Operating cash flow:
13.68x
Enterprise value / EBITDA:
13.07x
Gross Profit (TTM):
$1B
Return On Assets:
3.97%
Net Income Margin (TTM):
3.57%
Return On Equity:
7.23%
Return On Invested Capital:
5.39%
Operating Margin:
8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.2B | $2.3B | $556.2M | $587.7M | |
| Gross Profit | $960M | $986.4M | $1B | $244.6M | $250.1M | |
| Operating Income | $185.7M | $193.8M | $208.9M | $47.2M | $47M | |
| EBITDA | $258.8M | $140.4M | $226.2M | $60.5M | $52.2M | |
| Diluted EPS | $3.71 | $0.07 | $2.52 | $0.79 | $0.51 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $411.3M | $432.9M | $388.8M | $467.2M | $579.9M | |
| Total Assets | $1.6B | $1.9B | $2B | $2B | $2.1B | |
| Current Liabilities | $437.5M | $454.3M | $367.2M | $468.1M | $486M | |
| Total Liabilities | $845M | $988.8M | $912.5M | $933.9M | $938.7M | |
| Total Equity | $757.7M | $948.8M | $1.1B | $1.1B | $1.2B | |
| Total Debt | $311.3M | $448M | $456.1M | $402.2M | $381.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $97.6M | $117.8M | $211.7M | -$9.8M | $105.6M | |
| Cash From Investing | -$104.3M | $35.2M | -$9.1M | -$1M | -$2.4M | |
| Cash From Financing | -$90M | -$90.4M | -$51.1M | -$6.3M | -$15.1M | |
| Free Cash Flow | $91M | $105.1M | $203.5M | -$11M | $104M | |
AMED
Sector
Market Cap
$2.8B
$43.9M
Price % of 52-Week High
85.39%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-11.09%
-29.11%
Beta (5-Year)
0.726
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$85.16
200-day SMA
Sell
Level
$94.14
Bollinger Bands (100)
Sell
Level
90.08 - 98.88
Chaikin Money Flow
Buy
Level
50.9M
20-day SMA
Sell
Level
$87.05
Relative Strength Index (RSI14)
Sell
Level
28.58
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-70.1911
50-day SMA
Sell
Level
$91.61
MACD (12, 26)
Sell
Level
-2.04
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
9.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.7022)
Buy
CA Score
(Annual)
Level (0.2422)
Buy
Beneish M-Score
(Annual)
Level (-2.7857)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-6.8667)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Stock Forecast FAQ
In the current month, AMED has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AMED average analyst price target in the past 3 months is --.
-
Where Will Amedisys Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amedisys share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Amedisys?
Analysts are divided on their view about Amedisys share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amedisys is a Sell and believe this share price will drop from its current level to --.
-
What Is Amedisys's Price Target?
The price target for Amedisys over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AMED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amedisys is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AMED?
You can purchase shares of Amedisys via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amedisys shares.
-
What Is The Amedisys Share Price Today?
Amedisys was last trading at $84.56 per share. This represents the most recent stock quote for Amedisys. Yesterday, Amedisys closed at $84.49 per share.
-
How To Buy Amedisys Stock Online?
In order to purchase Amedisys stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
